Citations

Showing 10 of 108104 citations.

Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.
Yu, Cecilia, Tschautscher, Marcella , Briggler, Andrew M., Overman, Michael J. , Broaddus, Russell R. , Balcom, Jessica R. , Kipp, Benjamin R. , Grothey, Axel, Wang, Yucai , Loree, Jonathan M. , Meric‐Bernstam, Funda , Jones, Jeremy C , Kopetz, Scott

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3513-3513

10.1200/jco.2018.36.15_suppl.3513 Get It

Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database.
Grothey, Axel, Haller, Daniel G. , Gramont, Aimery de , Twelves, Christopher , Goldberg, Richard M. , Cheung, Winson Y. , André, Thierry , Kerr, Rachel , Dixon, Jesse G. , Alberts, Steven R. , O’Connell, Michael J. , Saltz, Leonard B. , Lonardi, Sara , Yoshino, Takayuki , Yothers, Greg , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3601-3601

10.1200/jco.2018.36.15_suppl.3601 Get It

Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.
Shields, Anthony F. , Sobrero, Alberto F. , Souglakos, Ioannis , Yamanaka, Takeharu , Vernerey, Déwi , Boukovinas, Ioannis , Kato, Takeshi , Kakolyris, Stylianos, Ou, Fang‐Shu , Paul, James , Yoshino, Takayuki , Taı̈eb, Julien , Shi, Qian , Kerr, Rachel , Labianca, Roberto , Torri, Valter , André, Thierry , Grothey, Axel , Meyerhardt, Jeffrey A. , Iveson, Timothy

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3599-3599

10.1200/jco.2018.36.15_suppl.3599 Get It

Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant trial: NCCTG N0147 (Alliance).
Lee, Hee Eun , Foster, Nathan R. , Smyrk, Thomas C. , Sinicrope, Frank A. , Shi, Qian , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3583-3583

10.1200/jco.2018.36.15_suppl.3583 Get It

Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).
Das, Rahul K, Innocenti, Federico , Cunha, Daniel Ferreira da , Rich, Kelly , Lenz, Heinz‐Josef , Niedzwiecki, Donna , Wuest, Diane, Hayete, Boris , Khalil, Iya, Niedzwiecki, Donna , Das, Rahul K, Furchtgott, Leon , Meyerhardt, Jeffrey A. , Nixon, Andrew B. , Cunha, Daniel, Rich, Kelly, O’Reilly, Eileen M. , Ou, Fang‐Shu , Latourelle, Jeanne C. , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3570-3570

10.1200/jco.2018.36.15_suppl.3570 Get It

A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
Cornell, Robert F. , Bishop, Michael R. , Larson, Sarah , Borrello, Ivan , Kumar, Shaji , Rossi, John M. , Thomrongsith, Lisa, Xue, Allen , Roberts, Zachary , Locke, Frederick L. , Bishop, Michael Russell , Orlowski, Robert Z. , Giralt, Sergio , Nooka, Ajay K. , Raje, Noopur

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS3103-TPS3103

10.1200/jco.2018.36.15_suppl.tps3103 Get It

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.
Lekakis, Lazaros J. , Jacobson, Caron A. , Jacobsen, Eric D. , Braunschweig, Ira , Oluwole, Olalekan O. , Deol, Abhinav , Bot, Adrian , Rossi, John M. , Jiang, Yizhou , Xue, Allen , Go, William Y., Neelapu, Sattva S. , Oluwole, Olalekan O , Locke, Frederick L. , Ghobadi, Armin , Miklos, David B. , Siddiqi, Tanya , Lin, Yi , Reagan, Patrick Michael , Farooq, Umar

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3039-3039

10.1200/jco.2018.36.15_suppl.3039 Get It

Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
Jacobson, Caron A. , Jacobsen, Eric D. , Lekakis, Lazaros J. , Braunschweig, Ira , Oluwole, Olalekan O. , Deol, Abhinav , Bot, Adrian , Jiang, Yizhou , Rossi, John M. , Xue, Allen , Go, William Y., Neelapu, Sattva S. , Oluwole, Olalekan O , Locke, Frederick L. , Ghobadi, Armin , Miklos, David B. , Lin, Yi , Siddiqi, Tanya , Reagan, Patrick Michael , Farooq, Umar

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3003-3003

10.1200/jco.2018.36.15_suppl.3003 Get It

Physician experience and understanding of clinical trial adverse event attribution.
Storrrick, Elizabeth M., Jatoi, Aminah , Mandrekar, Sumithra J. , Le‐Rademacher, Jennifer

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e14524-e14524

10.1200/jco.2018.36.15_suppl.e14524 Get It

Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades.
Siddiqui, Nauman , Purvey, Sneha , Hamal, Ruchi , Diasio, Robert B. , Saif, Wasif M., Zhang, Lulu

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2576-2576

10.1200/jco.2018.36.15_suppl.2576 Get It